The National Institutes of Health announced today that enrollment for the Adolescent Brain Cognitive Development (ABCD) Study is now complete and, in early 2019, scientists will have access to baseline data from all ABCD Study participants.
There are 11,874 youth, ages 9-10, participating in the study, including 2,100 young people who are twins or triplets. All will be followed through young adulthood.
The ABCD Study is a landmark study on brain development and child health that will increase understanding of environmental, social, genetic, and other biological factors that affect brain and cognitive development and can enhance or disrupt a young person’s life trajectory. Coordinated by the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, the study is supported by eight other NIH institutes and offices, as well as the Centers for Disease Control and Prevention and other federal partners.
The study—being conducted at 21 research sites around the country—will use advanced neuroimaging to observe brain development in children throughout adolescence, while tracking social, behavioral, physical and environmental factors that may affect brain development and other health outcomes.
Anonymized study data are being made available to the broad research community on a regular basis. This will allow scientists to analyze data and ask novel questions that were not even anticipated in the original study planning. Offering these data while the study is in progress means that both ABCD investigators and non-ABCD researchers will have access to the datasets to pursue their own research interests.
There are many health topics that are of interest to researchers, policy makers, educators, parents, and the participants themselves, which scientists can now study using the baseline assessment data. These data can then be tracked over time and used to make predictions as youth develop and are shaped by their life experiences. Scientists can look at brain characteristics associated with impulsive action or early psychopathology; the impact of health behaviors (e.g., sleep, physical activity) on cognitive and brain development; or traits associated with media use, including screen time exposure. For example, a recent study by ABCD investigators showed associations between differing amounts and kinds of screen time (e.g., video games vs. social media) and different structural brain characteristics, psychological traits, and cognitive function. Scientists will be able to follow participants over time to understand how media use will influence a person’s development, underscoring the unique opportunity provided by the ABCD study.
Similarly, researchers can look at risk and resilience factors for mental illness and substance use, including genetics, family history, traits such as impulsivity, and exposure to positive and negative environmental events. With longitudinal data, the developmental trajectories of the participants can be tracked to better understand these complex relationships, and eventually to improve prevention or mitigate risks for adverse outcomes.
Additional data from the first 4,500 children enrolled in the study will be released this month, and data from the full participant cohort (11,874) will be available in early 2019. In addition, scientists will be able access a new tool through the NIMH Data Archive — the Data Exploration and Analysis Portal (DEAP). DEAP will facilitate analysis of the ABCD data, allowing users to analyze the data online without downloading it, while providing appropriate statistical models and tools that take advantage of the ABCD Study design. DEAP will enhance the ability of researchers to address myriad questions related to adolescent development.
Researchers interested in accessing these data can visit the NIMH Data Archive. As findings are published in various journals by both ABCD investigators and other scientists, study coordinators will continue to post information on the study website at https://abcdstudy.org/scientists-publications.html.
The ABCD study is supported by the National Institute on Drug Abuse (NIDA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Mental Health, the National Institute on Minority Health and Health Disparities, the National Heart, Lung and Blood Institute, the National Institute of Neurological Disorders and Stroke, the NIH Office of Behavioral and Social Sciences Research, the NIH Office of Research on Women’s Health, and the Division of Adolescent and School Health at the Centers for Disease Control and Prevention (CDC), with additional partnerships with the National Institute of Justice, the CDC Division of Violence Prevention, the National Science Foundation, and the National Endowment for the Arts. For information on all study sites, go to https://abcdstudy.org/study-sites/.
Learn more about NIDA by following #ThisIsNIH on Twitter, Facebook, and Instagram when we take over NIH’s social media platforms from December 10-15. On Thursday, December 13, at 11am ET, join us on the NIH Facebook page for a live panel and Q&A with NIDA’s Director Dr. Nora Volkow about vaping.
NIDA Press Office
About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.nida.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®